Advertisement

Topics

Companies Related to "Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment" [Most Relevant Company Matches] RSS

10:19 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment" found in our extensive corporate database of over 50,000 company records.

Showing "Sitagliptin Versus Insulin Dose Increase Type Diabetes Insulin" Companies 1–25 of 1,000+

Extremely Relevant

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a propri...


Tandem Diabetes Care®, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...


Medtronic Diabetes

At Medtronic Diabetes, our 20 plus year history vividly reflects our dedication and ongoing vision to develop an "artificial pancreas". In 1983, we pioneered the idea of continuous insulin delivery, introducing our first insulin pump in an effort to find a "better way" to deliver insulin for people with diabetes. Since that time, Medtronic Diabetes has remained the market leader, earning a reputat...

Waratah Pharmaceuticals

Waratah is a dynamic young biopharmaceutical company founded in April 2000 as a spin-off of RTP Pharma Inc. to develop and commercialize products for its novel, patented therapy – Islet Neogenesis Therapy (I.N.T.™) for the treatment of insulin-dependent diabetes. Diabetes is a disease in which the body does not produce or properly use insulin because of damaged or destroyed insulin producing i...

DreaMed Diabetes

DreaMed Diabetes was established in 2014 to develop and commercialize diabetes treatment and management solutions. Its flagship product, GlucoSitter™, is a closed-loop insulin delivery system for patients with type 1 and type 2 diabetes. Additional development programs include insulin-treatment-profiling systems for diabetic clinics, patient decision-...

Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Loop and Inject services, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the levera...

Dance Pharma

Dance is a San Francisco based, global company focused exclusively on creating a line of small, patient friendly, pain-less, low cost insulin inhalers for the world diabetes market. In addition to providing inhaled insulin to those who have become insulin dependent, the company also intends to enable introduction of insulin much earlier in the disease proc...

Hygieia, Inc.

Hygieia, Inc. is an emerging diabetes health care company developing new ways to improve the effectiveness of therapy while reducing the cost of diabetes care. Hygieia’s first product is a handheld Diabetes Insulin Guidance System (DIGS™) designed to improve insulin therapy effectiveness for patients. DIGS works in a way that makes it a feasible ...

Novocell, Inc.

Novocell is a preclinical therapeutic company focused on diabetes. Our therapy is based on the encapsulation and implantation of pancreatic beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients. Our goal is that Pro-Islet-1 can free both Type 1 and Type 2 diabetic patients from insulin dependence on a long term basis, while reducing or eliminating hy...

Insulet Corporation

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump tha...

Medality Medical LLC

Medality Medical LLC, a privately funded (including an NIH grant) medical technology company, is focused on reversing type 2 diabetes and associated obesity. Its patented proprietary technology enables the gentle and selective extraction of excess mesenteric visceral fat, which has been associated with insulin resistance, a precursor to type 2 diabetes. In...

NiliMEDIX

NiliMEDIX develops innovative durable (to be used for several years) and disposable (replaced every 2-3 days) insulin pumps for helping diabetics manage their diabetes.Insulin pumps deliver insulin the way a healthy pancreas does allowing freedom in daily activities and improving the quality of life of their users.Moreover, the pumps usually decrease the needed daily amount of insulin by reducing ...

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

ImmunoMolecular Therapeutics

IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell fun...

Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction ...

DiObex, Inc.

DiObex is a biotechnology company engaged in the development of novel products for metabolic disease. DIO-901 (very low dose glucagon) is in development in two convenient delivery forms for the prevention of nocturnal hypoglycemia induced by insulin intensification. Insulin-induced hypoglycemia, which occurs most frequently at night, is a major limitation in the aggressive management of hype...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

MicroIslet

MicroIslet Inc. is a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes. MicroIslet has licensed several technologies from Duke University Medical Center that were developed over the last decade for the isolation, culture, storage and encapsulation of insulin-producing porcine ...

Ember Therapeutics, Inc.

Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Today’s rising epidemic of obesity and Type 2 diabetes coupled with the lack of innovation in the industry’s metabolic disorder treatment pipeline underscores the need for novel, ...

KeyVive.com

KeyVive (pronounced "key veev") derives from the French term "qui vive" and means "one who lives." The mission of KeyVive is to help people affected by diabetes succeed in living a healthy life by educating, informing and connecting individuals to each other. The Web site concept was conceived by Aimee and David Greenholtz as part of their effort to support those affected by diabetes. Aimee was di...

Mellitus Health

Founded in 2014 as Insulin Algorithms by Mayer Davidson, MD, Josh Davidson and Michael Margolese, the Los Angeles firm rebranded in 2018 as Mellitus Health, Inc. Its cloud-based insulin titration software works with all insulins and combinations and all 125 dosing regimens, providing precision insulin dosing recommendations to clinicians in just seconds. T...

Ember Therapeutics

Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Today’s rising epidemic of obesity and Type 2 diabetes coupled with the lack of innovation in the industry’s metabolic disorder treatment pipeline underscores the need for novel, ...

Calibra Medical Inc.

Calibra Medical Inc. is a medical device company developing small, simple, cost-effective drug delivery systems. The company’s first product, Finesse, is designed to improve mealtime insulin therapy delivery. Calibra is seeking to improve care for people with diabetes by simplifying insulin delivery, thereby improving patient adherence to their physic...

Glooko, Inc.

Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically syncs data from devices including blood glucose meters, insulin pumps, CGMs, smart insulin pens and many fitness and activity trackers. The broad variet...


More From BioPortfolio on "Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks